Sökning: onr:"swepub:oai:research.chalmers.se:c115fe02-5f82-4cd8-b278-f235f1cc60df" > Lopinavir/ritonavir...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05101naa a2200637 4500 | |
001 | oai:research.chalmers.se:c115fe02-5f82-4cd8-b278-f235f1cc60df | |
003 | SwePub | |
008 | 171007s2013 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:29e5b41c-a99d-4ff7-9340-2e255f07e7e0 | |
009 | oai:gup.ub.gu.se/173827 | |
009 | oai:prod.swepub.kib.ki.se:127008159 | |
024 | 7 | a https://doi.org/10.3109/00365548.2012.7569852 DOI |
024 | 7 | a https://research.chalmers.se/publication/1738272 URI |
024 | 7 | a https://lup.lub.lu.se/record/39210932 URI |
024 | 7 | a https://gup.ub.gu.se/publication/1738272 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1270081592 URI |
040 | a (SwePub)cthd (SwePub)lud (SwePub)gud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Andersson, Lars-Magnus,d 1968u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xalarh |
245 | 1 0 | a Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial. |
264 | c 2013-01-07 | |
264 | 1 | b Informa UK Limited,c 2013 |
520 | a Background: The objective of this study was to compare the efficacy of ritonavir boosted atazanavir versus ritonavir boosted lopinavir or efavirenz, all in combination with 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs), over 144 weeks in antiretroviral-naïve HIV-1-infected individuals. Methods: A prospective open-label randomized controlled trial was conducted at 29 sites in Sweden and Norway between April 2004 and December 2009. Patients were randomized to receive either efavirenz 600 mg once daily (EFV), or atazanavir 300 mg and ritonavir 100 mg once daily (AZV/r), or lopinavir 400 mg and ritonavir 100 mg twice daily (LPV/r). The primary endpoints were the proportion of patients with HIV-1 RNA 100,000 copies/ml at baseline had similar response rates in all arms. Conclusion: EFV was superior to LPV/r at week 48, but there were no significant differences between the 3 arms in the long-term (144 weeks) follow-up. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng |
653 | a treatment-naive patients | |
653 | a randomized controlled trial | |
653 | a HIV-1 | |
653 | a Combination antiretroviral therapy | |
653 | a Combination antiretroviral therapy | |
653 | a HIV-1 | |
653 | a treatment-naive patients | |
653 | a randomized controlled trial | |
653 | a Combination antiretroviral therapy; HIV-1; treatment-naive patients; randomized controlled trial | |
700 | 1 | a Vesterbacka, J.u Karolinska Institutet4 aut |
700 | 1 | a Blaxhult, Andersu Karolinska Institutet4 aut |
700 | 1 | a Flamholc, Leou Lund University,Lunds universitet,Enheten för infektionssjukdomar,Forskargrupper vid Lunds universitet,Infectious Diseases Research Unit,Lund University Research Groups4 aut0 (Swepub:lu)inf-lfl |
700 | 1 | a Nilsson, Staffan,d 1956u Gothenburg University,Göteborgs universitet,Institutionen för matematiska vetenskaper, matematisk statistik,Department of Mathematical Sciences, Mathematical Statistics4 aut0 (Swepub:gu)xnista |
700 | 1 | a Ormaasen, Vidaru Oslo universitetssykehus,Oslo University Hospital4 aut |
700 | 1 | a Sonnerborg, A.u Karolinska Institutet4 aut |
700 | 1 | a Gisslén, Magnus,d 1962u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xgissm |
710 | 2 | a Göteborgs universitetb Institutionen för biomedicin, avdelningen för infektionssjukdomar4 org |
773 | 0 | t Scandinavian Journal of Infectious Diseasesd : Informa UK Limitedg 45:7, s. 543-551q 45:7<543-551x 0036-5548x 1651-1980 |
856 | 4 | u http://dx.doi.org/10.3109/00365548.2012.756985y FULLTEXT |
856 | 4 8 | u https://doi.org/10.3109/00365548.2012.756985 |
856 | 4 8 | u https://research.chalmers.se/publication/173827 |
856 | 4 8 | u https://lup.lub.lu.se/record/3921093 |
856 | 4 8 | u https://gup.ub.gu.se/publication/173827 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:127008159 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy